Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

The deal gives Merck control of Verona’s Ohtuvayre, a newly approved treatment for chronic obstructive pulmonary disease ...

TUESDAY, July 1, 2025 (HealthDay News) — Digital inhalers may help predict the occurrence of acute exacerbations of chronic ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.